Abstract：Objective： To investigate the clinical application of endocrine therapy combined with robotic-assisted laparoscopic radical prostatectomy in oligometastatic prostate cancer in order to provide more reference for the treatment of prostate cancer patients with bone metastases. Methods： The clinical data of 33 prostate cancer patients with bone metastases （bone metastases ≤ 3） were retrospectively analyzed. According to different treatments, the patients were divided into endocrine therapy combined with robot-assisted laparoscopic radical prostatectomy group （combination therapy group, n=15） and endocrine therapy alone group （simple treatment group, n=18）. The serum PSA level and clinical progress during the follow-up period were compared between the two groups. Results： The patients in the combined treatment group were younger than those in the simple treatment group （P<0.05）, and there was no significant difference in other baseline data. In the combined treatment group, all 15 patients successfully completed the operations, 2 patients had lymph node metastasis and 13 samples had positive margins. The lowest value of PSA after treatment in the combined treatment group and the simple treatment group was 0.03 and 0.07 μg/L, respectively, and the progression rates of castration-resistant prostate cancer were 31.8% and 54.2%, respectively, and the difference was statistically significant （P<0.05）. Conclusion： Primary tumor debulking radical prostatectomy combined with endocrine therapy for oligometastatic prostate cancer is safe and feasible. There are no serious complications during and after operation, and it can significantly prolong the progression-free survival of patients, and the short-term curative effect is definite.
[1] BRAY F, FERLAY J, SOERJOMATARAM I, et al.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2018,68(6):394-424. [2] MOTTET N, BELLMUNT J, BOLLA M, et al.EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent[J].Eur Urol,2017,71(4):618-629. [3] VAN DEN BROECK T, VAN DEN BERGH R, ARFI N, et al. Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review[J]. Eur Urol,2019,75(6):967-987. [4] LIESENFELD L, KRON M, GSCHWEND J E.Prognostic factors for biochemical recurrence more than 10 years after radical prostatectomy[J]. J Urol,2017,197(1):143-148. [5] ROUVIÈRE, O, PUECHP, Renard-Penna R, et al. Use of prostate systematic and targeted biopsy on the basis of multiparametric MRI in biopsy-naive patients(MRI-FIRST):a prospective,multicentre,paired diagnostic study[J]. Lancet Oncol,2019,20(1):100-109. [6] LEEST V D, CORNEL E, ISRAEL B, et al.Head-to-head comparison of transrectal ultrasound-guided prostate biopsy versus multiparametric prostate resonance imaging with subsequent magnetic resonance-guided biopsy in biopsy-naive men with elevated prostate-specific antigen:A Large Prospective Multicenter Clinical Study[J]. Eur Urol,2018,75(4):570-578. [7] GUTIONTOV SI, PITRODA SP, WEICHSELBAUM RR.Oligometastasis: Past, Present, Future[J]. Int J Radiat Oncol Biol Phys,2020,108(3):530-538. [8] TOSOIAN J J, GORIN M A, ROSS A E, et al.Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations[J]. Nat Rev Urol,2017,14(1):15-25. [9] MANCEAU C, BEAUVAL J B, LESOURD M, et al.Confirmation by early oncologic outcomes after surgery of the accuracy of intermediate-risk prostate cancer classification based on magnetic resonance imaging staging and targeted biopsy[J]. Eur Urol Open Sci,2020,21(21):5-8. [10] COOKSON SM, AUS G, BURNETT AL, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer:the American Urological Association Prostate guidelines for localized prostate cancer update panel report and recommendations for a standard in the reporting of surgical outcomes[J]. J Urol,177(2):540-545. [11] CHIOFALO B, BRUNI S, CERTELLI C, et al.Primary debulking surgery vs. interval debulking surgery for advanced ovarian cancer: review of the literature and meta-analysis[J]. Minerva Med,2019,110(4):330-340. [12] HISHIDA T, MASAI K, KASEDA K, et al.Debulking surgery for malignant tumors: the current status, evidence and future perspectives[J]. Jpn J Clin Oncol,2021,51(9):1349-1362. [13] ZANON C, BORTOLINI M, CHIAPPINO I, et al.Cytoreductive surgery combined with intraperitoneal chemohyperthermia for the treatment of advanced colon cancer[J]. World J Surg,2006,30(11):2025-2032. [14] ESPOSITO E, SIANI C, PACE U, et al.Debulking mastectomy with electrochemotherapy:a case report of no surgery approach to recurrent breast cancer.Transl[J]. Cancer Res,2021,10(2):1144-1149. [15] OAKLAND R J, FURTADO N R, TIMOTHY J, et al.The biomechanics of vertebroplasty in multiple myeloma and metastatic bladder cancer: a preliminary cadaveric investigation[J]. J Neurosurg Spine,2008,9(5):493-501. [16] THOMAS B, DANIELA OL, LISA M, et al.A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer[J]. Eur Urol,2021,80(5):531-545. [17] TEETER A E, GRIFFIN K, HOWARD L E, et al.Does early prostate specific antigen doubling time after radical prostatectomy, calculated prior to prostate specific antigen recurrence, correlate with prostate cancer outcomes? a report from the SEARCH database group[J]. J Urol,2018,199(3):713-718. [18] DEVOS G, DEVLIES W, DE M G, et al.Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer[J]. Nat Rev Urol,2021,18(12):739-762.
